Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 6.33
-0.03 (-0.47%)
Apr 2, 2026, 4:08 PM HKT
Sino Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 31,834 | 28,866 | 26,199 | 26,026 | 26,861 | |
Revenue Growth (YoY) | 10.28% | 10.18% | 0.67% | -3.11% | 13.59% |
Cost of Revenue | 5,708 | 5,336 | 4,990 | 4,488 | 5,332 |
Gross Profit | 26,127 | 23,530 | 21,210 | 21,539 | 21,529 |
Selling, General & Admin | 13,137 | 12,159 | 11,067 | 11,709 | 12,704 |
Research & Development | 5,866 | - | - | - | - |
Other Operating Expenses | 832.43 | 5,569 | 4,704 | 4,444 | 4,193 |
Operating Expenses | 19,835 | 17,729 | 15,770 | 16,153 | 16,896 |
Operating Income | 6,291 | 5,801 | 5,439 | 5,386 | 4,633 |
Interest Expense | -278.31 | -295.12 | -495.24 | -429.49 | -308.62 |
Interest & Investment Income | 2,372 | 1,347 | 611.38 | 472.38 | 559.89 |
Earnings From Equity Investments | -151.38 | -118.3 | -525.71 | -152.98 | 13,631 |
Currency Exchange Gain (Loss) | 21.06 | -123.41 | -96.02 | 138.22 | 292.3 |
Other Non Operating Income (Expenses) | 277.06 | 359.43 | 570.2 | 185.84 | 488.2 |
EBT Excluding Unusual Items | 8,532 | 6,971 | 5,504 | 5,600 | 19,295 |
Impairment of Goodwill | - | -18.62 | - | - | - |
Gain (Loss) on Sale of Investments | -1,548 | -1,483 | -46.9 | -449.08 | -265.38 |
Gain (Loss) on Sale of Assets | 11.17 | 163.47 | 57.02 | 3.47 | -4.28 |
Asset Writedown | -71.92 | -286.81 | - | -19.4 | -441.1 |
Other Unusual Items | 20.43 | -68.09 | -104.06 | 80.08 | -12.02 |
Pretax Income | 6,943 | 5,277 | 5,410 | 5,215 | 18,573 |
Income Tax Expense | 1,629 | 492.92 | 797.27 | 696.72 | 1,958 |
Earnings From Continuing Operations | 5,315 | 4,785 | 4,613 | 4,518 | 16,615 |
Earnings From Discontinued Operations | - | 1,580 | 484.76 | 484.47 | - |
Net Income to Company | 5,315 | 6,365 | 5,097 | 5,003 | 16,615 |
Minority Interest in Earnings | -2,971 | -2,865 | -2,765 | -2,459 | -2,006 |
Net Income | 2,343 | 3,500 | 2,332 | 2,544 | 14,608 |
Net Income to Common | 2,343 | 3,500 | 2,332 | 2,544 | 14,608 |
Net Income Growth | -33.04% | 50.08% | -8.32% | -82.59% | 427.17% |
Shares Outstanding (Basic) | 18,002 | 18,294 | 18,529 | 18,622 | 18,769 |
Shares Outstanding (Diluted) | 18,057 | 18,295 | 18,529 | 19,017 | 19,283 |
Shares Change (YoY) | -1.30% | -1.26% | -2.57% | -1.38% | 2.57% |
EPS (Basic) | 0.13 | 0.19 | 0.13 | 0.14 | 0.78 |
EPS (Diluted) | 0.13 | 0.19 | 0.13 | 0.12 | 0.73 |
EPS Growth | -32.13% | 51.97% | 3.55% | -83.41% | 397.00% |
Free Cash Flow | - | 5,655 | 4,998 | 5,022 | 3,652 |
Free Cash Flow Per Share | - | 0.31 | 0.27 | 0.26 | 0.19 |
Dividend Per Share | 0.090 | 0.065 | 0.044 | 0.106 | 0.065 |
Dividend Growth | 37.68% | 46.97% | -58.16% | 62.87% | 5.59% |
Gross Margin | 82.07% | 81.51% | 80.95% | 82.76% | 80.15% |
Operating Margin | 19.76% | 20.10% | 20.76% | 20.69% | 17.25% |
Profit Margin | 7.36% | 12.12% | 8.90% | 9.77% | 54.38% |
Free Cash Flow Margin | - | 19.59% | 19.08% | 19.30% | 13.60% |
EBITDA | 7,383 | 6,893 | 6,379 | 6,254 | 5,453 |
EBITDA Margin | 23.19% | 23.88% | 24.35% | 24.03% | 20.30% |
D&A For EBITDA | 1,092 | 1,092 | 939.85 | 868.56 | 820.57 |
EBIT | 6,291 | 5,801 | 5,439 | 5,386 | 4,633 |
EBIT Margin | 19.76% | 20.10% | 20.76% | 20.69% | 17.25% |
Effective Tax Rate | 23.46% | 9.34% | 14.74% | 13.36% | 10.54% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.